Your browser is no longer supported. Please, upgrade your browser.
ADPT Adaptive Biotechnologies Corporation daily Stock Chart
Adaptive Biotechnologies Corporation
Index- P/E414.85 EPS (ttm)0.07 Insider Own1.50% Shs Outstand134.52M Perf Week-5.49%
Market Cap3.79B Forward P/E- EPS next Y-0.84 Insider Trans-17.46% Shs Float110.64M Perf Month-3.88%
Income-62.10M PEG- EPS next Q-0.20 Inst Own65.90% Short Float4.49% Perf Quarter-9.06%
Sales78.10M P/S48.59 EPS this Y-8.50% Inst Trans0.30% Short Ratio6.72 Perf Half Y-26.78%
Book/sh4.71 P/B5.99 EPS next Y16.80% ROA- Target Price44.75 Perf Year-
Cash/sh4.26 P/C6.62 EPS next 5Y- ROE- 52W Range24.05 - 55.12 Perf YTD-5.72%
Dividend- P/FCF- EPS past 5Y- ROI19.30% 52W High-50.20% Beta-
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin72.30% 52W Low14.14% ATR1.49
Employees346 Current Ratio8.20 Sales Q/Q51.70% Oper. Margin- RSI (14)39.81 Volatility4.51% 4.96%
OptionableYes Debt/Eq0.04 EPS Q/Q82.90% Profit Margin- Rel Volume1.15 Prev Close28.21
ShortableYes LT Debt/Eq0.04 EarningsFeb 11 AMC Payout- Avg Volume738.91K Price27.45
Recom1.30 SMA20-7.75% SMA50-5.59% SMA200-20.30% Volume292,724 Change-2.69%
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Jan-13-20 07:30AM  Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients GlobeNewswire
Jan-08-20 07:30AM  Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia GlobeNewswire
Dec-30-19 04:05PM  Adaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
10:04AM  Top Ranked Momentum Stocks to Buy for December 30th Zacks
Dec-26-19 02:47PM  Tech will drive change in health care throughout next decade American City Business Journals
Dec-20-19 04:17PM  Is Adaptive Biotechnologies Corporation (ADPT) A Good Stock To Buy? Insider Monkey +7.21%
Dec-16-19 09:24PM  Chad Robins led Adaptive Biotechnologies through a huge 2019 American City Business Journals
Dec-13-19 04:52AM  Adaptive Biotechnologies Shares March Higher, Can It Continue? Zacks
Dec-09-19 08:44AM  Fiverr Languishes Below IPO Price as First Chance to Sell Nears Bloomberg
08:00AM  Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay GlobeNewswire
Dec-04-19 04:30PM  Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients GlobeNewswire
Dec-03-19 04:34PM  Hedge Funds Love Echostar Corporation (SATS) Way More Than These 4 Stocks Insider Monkey
Nov-22-19 03:01AM  Seattle has potential as a biotech hub, but more companies must stay here and grow American City Business Journals
Nov-19-19 12:26PM  Robertson's Tiger Management Buys Adobe, Facebook
Nov-12-19 04:05PM  Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-11-19 09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
Oct-29-19 04:05PM  Adaptive Biotechnologies to Report Third Quarter Financial Results on November 12, 2019 GlobeNewswire
Oct-14-19 06:43PM  Hedge Funds Have Never Been This Bullish On Adaptive Biotechnologies Corporation (ADPT) Insider Monkey
Oct-09-19 08:37AM  Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits Zacks
Sep-26-19 07:13AM  Do Insiders Own Shares In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)? Simply Wall St. -7.92%
Sep-25-19 08:44AM  Illumina (ILMN) Inks Deal to Develop Distributable Test Kits Zacks -6.47%
Sep-24-19 08:00AM  Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx GlobeNewswire -7.77%
Sep-17-19 08:00AM  Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgens Hematology Franchise GlobeNewswire
Sep-08-19 07:45PM  Here's Why Adaptive Biotechnologies Rose 31.9% in August Motley Fool
Aug-16-19 04:22PM  Andreas Halvorsen's Top 5 Buys of the 2nd Quarter
Aug-14-19 09:05AM  Adaptive Biotechnologies stock down 8.5% in premarket trade MarketWatch
Aug-13-19 04:28PM  Adaptive Biotech loss narrower than expected on first post IPO report MarketWatch
04:05PM  Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-12-19 06:57PM  Ron Baron Comments on Adaptive Biotechnologies Corp
Aug-09-19 04:56PM  New Listings Stink Up Earnings Season After Reports Disappoint Bloomberg
Aug-07-19 05:20PM  Adaptive Biotechnologies signs lease for new Seattle headquarters American City Business Journals +7.17%
08:30AM  Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattles Growing Biotech Hub GlobeNewswire
Aug-01-19 04:15PM  Adaptive Biotechnologies to Report Second Quarter Financial Results on August 13, 2019 GlobeNewswire
Jul-31-19 04:15PM  Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers GlobeNewswire
Jul-24-19 07:10AM  3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Jul-12-19 03:55PM  Sound Pharmaceuticals targets IPO in 2020 American City Business Journals
Jul-01-19 04:32PM  Why Freeport-McMoRan, Coty, and Adaptive Biotechnologies Slumped Today Motley Fool -16.98%
04:05PM  Adaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
10:28AM  Adaptive Biotechnologies CEO Chad Robins on that crazy IPO and working with his older brother MarketWatch
Jun-28-19 03:14PM  Recent IPOs show investor appetite is strong for biotechs Yahoo Finance +19.85%
09:25AM  Physicist and His Financier Brother Net $5 Billion Biotech IPO Bloomberg
Jun-27-19 04:32PM  Adaptive Biotechnologies Shares Double After IPO
02:48PM  Change Healthcare & Adaptive Biotechnologies pop on first trading day Yahoo Finance Video
11:40AM  Adaptive Biotechnologies IPO: Five things to know MarketWatch
11:25AM  Adaptive Biotech and BridgeBio shares rocket higher on their first day of trade MarketWatch
11:14AM  Adaptive Biotechnologies starts trading today Yahoo Finance Video
08:31AM  Adaptive Biotechnologies prices IPO at $20 a share, above previous range of $18 to $19 MarketWatch
07:00AM  Adaptive Biotechnologies Corporation (Nasdaq: ADPT) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
02:20AM  Adaptive Biotechnologies takes flight in IPO debut Financial Times
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBINS HARLAN SChief Scientific OfficerJan 17Option Exercise6.323,70023,38474,379Jan 17 05:29 PM
ROBINS HARLAN SChief Scientific OfficerJan 17Sale27.963,700103,44970,679Jan 17 05:29 PM
ROBINS HARLAN SChief Scientific OfficerJan 16Option Exercise6.323,70023,38474,379Jan 17 05:29 PM
ROBINS HARLAN SChief Scientific OfficerJan 16Sale28.833,700106,65670,679Jan 17 05:29 PM
ROBINS HARLAN SChief Scientific OfficerJan 15Option Exercise6.323,70023,38474,379Jan 17 05:29 PM
ROBINS HARLAN SChief Scientific OfficerJan 15Sale29.523,700109,22470,679Jan 17 05:29 PM
Taylor Stacy LSVP and General CounselJan 08Option Exercise6.556624,3361,962Jan 10 05:00 PM
Cohen Chad MChief Financial OfficerJan 08Option Exercise4.0720,00081,40021,000Jan 10 05:00 PM
Cohen Chad MChief Financial OfficerJan 08Sale29.8720,000597,4001,000Jan 10 05:00 PM
Taylor Stacy LSVP and General CounselJan 08Sale30.0066219,8601,300Jan 10 05:00 PM
HILL NANCY LOUISESVP, OperationsJan 06Option Exercise0.8460,00050,40070,000Jan 07 09:00 PM
HILL NANCY LOUISESVP, OperationsJan 06Sale29.1460,0001,748,40010,000Jan 07 09:00 PM
RUBINSTEIN JULIEPresidentDec 31Option Exercise0.8440,00033,60040,000Jan 03 04:15 PM
DOBMEIER ERICDirectorDec 31Option Exercise6.325,00031,6005,000Jan 03 04:15 PM
RUBINSTEIN JULIEPresidentDec 31Sale30.0040,0001,200,0000Jan 03 04:15 PM
RUBINSTEIN JULIEPresidentDec 30Option Exercise0.4555,00024,75055,000Dec 31 07:52 AM
RUBINSTEIN JULIEPresidentDec 30Sale28.5555,0001,570,1850Dec 31 07:52 AM
RUBINSTEIN JULIEPresidentDec 27Option Exercise0.4580,00036,00080,000Dec 31 07:52 AM
RUBINSTEIN JULIEPresidentDec 27Sale29.2880,0002,342,4000Dec 31 07:52 AM
RUBINSTEIN JULIEPresidentDec 26Option Exercise0.3880,00030,60080,000Dec 27 04:15 PM
DOBMEIER ERICDirectorDec 26Option Exercise6.3215,00094,80015,000Dec 30 04:14 PM
RUBINSTEIN JULIEPresidentDec 26Sale29.3780,0002,349,6000Dec 27 04:15 PM
RUBINSTEIN JULIEPresidentDec 24Option Exercise0.3380,00026,40080,000Dec 27 04:15 PM
RUBINSTEIN JULIEPresidentDec 24Sale30.0980,0002,407,4600Dec 27 04:15 PM